Shares of Geron surged this morning after the biotech announced that it had inked a collaboration deal with Merck to develop a cancer vaccine that targets telomerase. Telomerase promotes cancer growth. Details were in short supply, but Geron gains an upfront payment, milestones and a pledge by Merck to take an equity stake in its next round of venture capital.
- read this AP story for more